| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Tuesday, September 25, 2018 Novartis CEO Vas Narasimhan is seeking to cut the company's workforce from 124,000 to under 100,000 by 2022 as the company grapples with major marketing and manufacturing issues. |
|
|
Top Stories Of The Week Tuesday, September 25, 2018 The top 10 drugmakers in 2024 will hold 35% of the total biopharma market share, or more than $420 billion in sales that year. Wednesday, September 26, 2018 Alexion’s rebuilding plan has continued with another bolt-on acquisition, this time a $400 million upfront deal for rare disease specialist Syntimmune. Monday, September 24, 2018 Despite being one of the lowest-paid pharma CEOs, Pascal Soriot says defeating a Pfizer takeover was right for AstraZeneca. Tuesday, September 25, 2018 Novartis’ traditional pill manufacturing will shoulder the brunt of a cost-cutting effort announced Tuesday as it looks to a future in biologic drugs and higher margins. Tuesday, September 25, 2018 TG Therapeutics has abandoned plans to seek accelerated FDA approval of its ublituximab-umbralisib combination in chronic lymphocytic leukemia. The biotech made the decision because its phase 3 overall response rate data “were not sufficiently mature to conduct the analysis.” Friday, September 21, 2018 uBiome, which sells sequencing-based microbiome tests, is moving into therapeutics with $83 million in new funding, a new site in Cambridge, Massachusetts, and a new board member: former Novartis CEO Joe Jimenez. Friday, September 21, 2018 HIV can hide in the body in “reservoirs” that can resurge at any time. Scientists at the University of North Carolina are reporting progress in their efforts to use immunotherapy—a technology that’s most closely associated with oncology—to eradicate these reservoirs. Wednesday, September 26, 2018 In a draft guidance statement, the FDA proposed levying heavy fines on pharmaceutical companies and CROs that don’t post clinical trial results online. Thursday, September 20, 2018 GlaxoSmithKline’s H1N1 flu vaccine Pandemrix made waves around 2010 after increased cases of narcolepsy emerged among children who took it in the previous pandemic. But a report by The BMJ suggests greater safety problems with the shot, which neither GSK nor health authorities have made public. Monday, September 24, 2018 Call it a promise kept. For years, Amarin has staunchly defended its heart drug Vascepa, despite detractors' disbelief that the drug truly cut cardiovascular risks. According to a new study, it does—and in a big way. Resources Presented by: Catalent Learn the best strategies for attracting investors in early phases of development and for overcoming formulation challenges. Sponsored by: Amazon Web Services Download our new eBook to learn how Healthcare and Life Sciences organizations are taking advantage of solutions from AWS and the AWS Partner Network to obtain value from critical data. Sponsored by: Covance FSPx Covance FSPx boasts one of the world’s largest dedicated FSP groups in the contract research organization space with ~4200 staff in 60+ countries. Sponsored by: Covance FSPx Covance FSPx boasts one of the world’s largest dedicated FSP groups in the contract research organization space with ~4200 staff in 60+ countries. Sponsored by: Reprints Desk, Inc. Go from Search to Full-Text Scientific Papers in a Single Click! Sponsored by: Docusign Life sciences companies must immediately identify and realize productivity gains to drive down operational costs—or risk seeing more nimble competitors disappear into the distance. Where to begin? Sponsored by: Veeva A top 20 pharma and growing biotech re-engineer regulatory processes. Sponsored by: Sciformix Are automation, big data and artificial intelligence (AI) a key part of your company’s pharmacovigilance strategy? Read this whitepaper to know what they should be! Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. Sponsored by: Patheon, part of Thermo Fisher Scientific When developing a parenteral, pharmaceutical scientists are faced with a variety of choices – choices that can be conflicting or present differing advantages. Sponsored by: Baxter Baxter BioPharma Solutions’ whitepaper offers a method to address the challenges of tech transfer for lyophilized products from lab-scale to commercial-scale. Sponsored by: Blue Matter A whitepaper outlining the key commercial challenges facing rare disease products, and how biopharmaceutical companies can overcome them. Sponsored by: AWS and Tableau Inova is using the capabilities of Tableau on AWS to identify biomarkers for personalized treatment intended to improve health outcomes for children. Sponsored by: AWS and Reltio Reltio and IQVIA provide holistic data management solutions for traditional pharma, emerging biotech, and consumer health companies, on AWS. Presented by: AWS and Druva Life Sciences organizations are embracing cloud-based Master Data Management (MDM) to modernize the organization of critical data. Sponsored by: Catalent Develop a basic understanding of principles and concepts of bioavailability of oral drugs. | 